Literature DB >> 33676445

Social cognition in individuals with 22q11.2 deletion syndrome and its link with psychopathology and social outcomes: a review.

Branka Milic1, Clémence Feller2, Maude Schneider2, Martin Debbané3,4, Henriette Loeffler-Stastka5.   

Abstract

BACKGROUND: The 22q11.2 deletion syndrome (22q11DS) is a genetic syndrome that results in a highly variable profile of affected individuals of which impairments in the social domain and increased psychopathology are the most prominent. Notably, 25-30% of affected individuals eventually develop schizophrenia/psychosis, predisposing persons with the syndrome to increased risk for this disorder. Because social cognition is considered to underlie social behavior and to be related to psychopathology, this systematic review investigated social cognition in individuals with 22q11DS and examined reported links across its domains with psychopathology and social outcomes. This can provide the basis for a closer understanding of the path from risk to disorder and will inform on the specific domains that can be targeted with preventive intervention strategies.
METHOD: Systematic literature review of studies that reported the links between social cognitive domains and psychopathology and/or social outcomes in individuals with 22q11DS. Electronic databases searched were PubMed and PsycINFO.
RESULTS: Defined eligibility criteria identified a total of ten studies to be included in the present review. Selected studies investigated links between two domains of social cognition (emotion processing and theory of mind (ToM)) and psychopathology and/or social outcomes. With respect to the links to psychopathology, two aspects of social cognition were related primarily to negative symptoms. Results regarding the associations to positive and emotional symptoms (anxiety/depression) are limited and require further investigation. Even though both aspects of social cognition were associated with social outcomes, several studies also found no links between these two domains. Both reports invite for an additional examination of reported results and specific considerations regarding chosen constructs.
CONCLUSION: Although equivocal, results of the present review provide sufficient evidence that social cognition is a useful domain for the closer elucidation of clinical outcomes and social difficulties in this population. At the same time, longitudinal studies and consideration of other variables are also necessary for a timely understanding of affected persons in this respect.

Entities:  

Keywords:  22q11DS; Emotion processing; Mentalizing; Preventive interventions; Psychopathology; Psychosis; Schizophrenia; Social cognition; Social outcomes; Theory of mind; ToM

Year:  2021        PMID: 33676445      PMCID: PMC7936464          DOI: 10.1186/s12888-020-02975-5

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


  93 in total

1.  Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data.

Authors:  J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-07       Impact factor: 8.829

2.  Adolescents at ultra-high risk for psychosis with and without 22q11 deletion syndrome: a comparison of prodromal psychotic symptoms and general functioning.

Authors:  Marco Armando; Paolo Girardi; Stefano Vicari; Deny Menghini; Maria Cristina Digilio; Maria Pontillo; Riccardo Saba; Luigi Mazzone; Ashleigh Lin; Claudia M Klier; Miriam R Schäfer; G Paul Amminger
Journal:  Schizophr Res       Date:  2012-05-23       Impact factor: 4.939

Review 3.  The functional significance of social cognition in schizophrenia: a review.

Authors:  Shannon M Couture; David L Penn; David L Roberts
Journal:  Schizophr Bull       Date:  2006-08-17       Impact factor: 9.306

4.  Neurocognitive development in 22q11.2 deletion syndrome: comparison with youth having developmental delay and medical comorbidities.

Authors:  R E Gur; J J Yi; D M McDonald-McGinn; S X Tang; M E Calkins; D Whinna; M C Souders; A Savitt; E H Zackai; P J Moberg; B S Emanuel; R C Gur
Journal:  Mol Psychiatry       Date:  2014-01-21       Impact factor: 15.992

5.  Candidate socioemotional remediation program for individuals with intellectual disability.

Authors:  Bronwyn Glaser; Amelie Lothe; Mélanie Chabloz; Daniel Dukes; Catherine Pasca; Jérôme Redoute; Stephan Eliez
Journal:  Am J Intellect Dev Disabil       Date:  2012-09

6.  Social cognitive impairments and psychotic symptoms: what is the nature of their association?

Authors:  Anne-Kathrin J Fett; Arija Maat
Journal:  Schizophr Bull       Date:  2011-06-22       Impact factor: 9.306

7.  A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population.

Authors:  Lorenzo D Botto; Kristin May; Paul M Fernhoff; Adolfo Correa; Karlene Coleman; Sonja A Rasmussen; Robert K Merritt; Leslie A O'Leary; Lee-Yang Wong; E Marsha Elixson; William T Mahle; Robert M Campbell
Journal:  Pediatrics       Date:  2003-07       Impact factor: 7.124

8.  Social cognition in 22q11.2 microdeletion syndrome: relevance to psychosis?

Authors:  Maria Jalbrzikowski; Chelsea Carter; Damla Senturk; Carolyn Chow; Jessica M Hopkins; Michael F Green; Adriana Galván; Tyrone D Cannon; Carrie E Bearden
Journal:  Schizophr Res       Date:  2012-10-31       Impact factor: 4.939

9.  Predominant negative symptoms in 22q11.2 deletion syndrome and their associations with cognitive functioning and functional outcome.

Authors:  Maude Schneider; Martial Van der Linden; Sarah Menghetti; Bronwyn Glaser; Martin Debbané; Stephan Eliez
Journal:  J Psychiatr Res       Date:  2013-10-25       Impact factor: 4.791

10.  The psychosocial impact of 22q11 deletion syndrome on patients and families: A systematic review.

Authors:  Oanh Kieu Vo; Alisdair McNeill; Katharina Sophie Vogt
Journal:  Am J Med Genet A       Date:  2018-03-25       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.